TUBIZE-FIN And 3 Other Stocks Have Very High Payout Ratio

(VIANEWS) – KPN KON (KPN.AS), CROSSWOOD (CROS.PA), ELIS (ELIS.PA) are the highest payout ratio stocks on this list.

We have gathered information concerning stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.

When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. KPN KON (KPN.AS)

77.22% Payout Ratio

Koninklijke KPN N.V. provides telecommunications and information technology (IT) services in the Netherlands. It operates through Consumer; Business; Wholesale; and Network, Operations & IT segments. The company offers fixed and mobile telephony, fixed and mobile broadband internet, and television services to retail and business consumers; infrastructure and network related IT solutions to business customers; and wholesale network services to third parties. It also provides IT services, includes connectivity, cloud, security, workspace, and cybersecurity services; interconnect traffic, visitor roaming, and digital products; and NL-ix, an interconnect exchange, as well as sells handsets and peripheral equipment, and software licenses. The company was founded in 1881 and is headquartered in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, KPN KON has a trailing twelve months EPS of €0.18.

PE Ratio

KPN KON has a trailing twelve months price to earnings ratio of 17.26. Meaning, the purchaser of the share is investing €17.26 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.83%.

Moving Average

KPN KON’s value is under its 50-day moving average of €3.27 and above its 200-day moving average of €3.06.

Sales Growth

KPN KON’s sales growth is 2.4% for the ongoing quarter and 1.7% for the next.

Volume

Today’s last reported volume for KPN KON is 1925510 which is 83.64% below its average volume of 11773200.

More news about KPN KON.

2. CROSSWOOD (CROS.PA)

51.06% Payout Ratio

Crosswood SA engages in real estate activity in France. Its property portfolio includes shops and offices, and housing properties. The company was formerly known as Desquenne et Giral. Crosswood SA was incorporated in 1935 and is based in Paris, France. Crosswood SA operates as a subsidiary of Compagnie Financiere De Broceliande.

Earnings Per Share

As for profitability, CROSSWOOD has a trailing twelve months EPS of €0.57.

PE Ratio

CROSSWOOD has a trailing twelve months price to earnings ratio of 14.65. Meaning, the purchaser of the share is investing €14.65 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.48%.

Volume

Today’s last reported volume for CROSSWOOD is 60 which is 82.24% below its average volume of 338.

More news about CROSSWOOD.

3. ELIS (ELIS.PA)

43.02% Payout Ratio

Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.

Earnings Per Share

As for profitability, ELIS has a trailing twelve months EPS of €0.87.

PE Ratio

ELIS has a trailing twelve months price to earnings ratio of 19.92. Meaning, the purchaser of the share is investing €19.92 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.57%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 25, 2022, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 2.31%.

More news about ELIS.

4. TUBIZE-FIN (TUB.BR)

39.2% Payout Ratio

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.

Earnings Per Share

As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.92.

PE Ratio

TUBIZE-FIN has a trailing twelve months price to earnings ratio of 38.75. Meaning, the purchaser of the share is investing €38.75 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.

More news about TUBIZE-FIN.

Leave a Reply

Your email address will not be published. Required fields are marked *